


Lilly's 26 deals in 2026 span every major therapy area and modality

Of \$53B in disclosed value, only ~\$13B is upfront cash, concentrated in a handful of large buyouts



Competitive intelligence analysis of Eli Lilly business development, January to July 16, 2026. 26 disclosed transactions: 25 year-to-date plus AtaiBeckley (announced July 16), excluding the Cialis divestment. Each deal placed by its lead asset's therapy area and modality; platform and cross-TA technology deals sit in the bottom row. Bubble size is total disclosed value; figures inside are upfront cash. Ring = M&A acquisition; no ring = licensing or collaboration. Gold diamond = China-based partner. Sources: company press releases and public deal records.